ILEXIUM 2024

Munich, Germany

Thu, 27 June 2024 - Fri, 28 June 2024

Starting soon

00 years
00 months
00 days
00 hours
00 minutes
00 seconds

Registration

For the 4th time we will come together to share and discuss global advances in the treatment of cancer patients in the field of intraoperative radiotherapy (IORT). We look forward to welcoming ýou in Munich for the International Low Energy X-ray IORT User Meeting (ILEXIUM) 2024.

During two days of professional talks, peer insights and discussions you will learn the latest updates on the use of IORT in clinical practice.

Use this opportunity to connect with other experts in the IORT field from around the world and share first-hand experiences.

Registrations are open now until June 20, 2024.

Conference Chair Frank Giordano, MD Professor & Chair, Department of Radiation Oncology,
University Medical Center Mannheim, Germany

Conference Chair Elena Sperk, MD Director Mannheim Cancer Center (MCC) Clinical Trials Unit,
University Medical Center Mannheim, Germany

Conference Chair Stephanie E. Combs, MD Professor and Chair, Department of Radiation Oncology & Munich Institute of Biomedical Engineering,
Dean, School of Medicine and Health
Technical University of Munich, Germany

Program

The scientific symposium will address a variety of topics related to intraoperative radiotherapy (IORT) with a focus on the latest clinical updates, new data, recent guidelines and further developments. Although the focus is on breast cancer and brain tumor patients, other real-world applications as well as interdisciplinary topics like health economics will be represented in the program.

	Session	Speaker
12:00 - 12:30 PM	Welcome reception & opening remarks	Frank Giordano, Elena Sperk, Stephanie Combs, Germany

	Session	Speaker
12:30 - 1:00 PM	Key note lecture: New concepts for the treatment of early stage breast cancer	Hans-Christian Kolberg, Germany
1:00 - 1:15 PM	Breast-IORT in major clinical trials	Steffi Pigorsch, Germany
1:15 - 1:30 PM	IORT in recurrent breast cancer	Hans-Christian Kolberg, Germany
1:30 - 1:45 PM	Update of RIOMA Trial. Preliminary results of intraoperative irradiation of breast cancer patients in Spain	Javier Sanz, Spain
1:45 - 2:00 PM	Las Palmas experience combining hypofractionation and INTRABEAM boost	Pedro Lara, Spain
2:00 - 2:15 PM	Local recurrence after Lumpectomy with and without IORT: A single-center experience from Malaysia	Yip Cheng Hair, Malaysia
2:15 - 2:40 PM	Break

	Session	Speaker
2:40 - 3:10 PM	Breast cancer treatment options from a patient’s perspective - supported by randomised evidence & case report	Jayant Vaidya + Marcelle Bernstein, United Kingdom
3:10 - 3:25 PM	Cosmetic outcome in IORT patients	Elena Sperk, Germany
3:25 - 3:40 PM	Planned but not executed IORT	Marc Sütterlin, Germany
3:40 - 3:55 PM	Health-related QoL and patient satisfaction of Filipinos after breast conservation surgery and IORT	Angeli Andrea Cocos, Philippines
3:55 - 4:10 PM	Break

	Session	Speaker
4:10 - 4:25 PM	Evidence and clinical practice in lower gastrointestinal cancer	Marc Münter, Germany
4:25 - 4:40 PM	Pancreas Cancer IORT: Rationale & feasibility	Tamer Refaat, United States of America
4:40 - 4:55 PM	Evidence and procedures for IORT of head & neck cancers	William Small, United States of America
4:55 - 5:10 PM	Treating sarcomas with IORT: Opportunities and expectations	Gustavo Sarria, Germany

	Session	Speaker
5:10 - 5:20 PM	Closing remarks	Frank Giordano, Elena Sperk, Stephanie Combs, Germany

Augustiner-Keller, Arnulfstraße 52, 80335 Munich
Thu, 27 June 2024, 19:00-23:00 CEST

Add to Calendar

Chair William Small Loyola University Medical Center, United States of America

Chair Frederik Wenz University Hospital Freiburg, Germany

Chair Pedro Lara San Roque University Hospital, Spain

	Session	Speaker
8:30 - 8:40 AM	Welcome reception & opening remarks	Frank Giordano, Elena Sperk, Stephanie Combs, Germany
8:40 - 8:50 AM	Back to the roots: 50kV IORT for Brain Tumors	Frank Giordano, Germany

	Session	Speaker
8:50 - 9:10 AM	Opportunities and challenges in brain tumor treatment	Christina Tsien, Canada
9:10 - 9:25 AM	Safety profile of IORT for treating Glioblastoma. Data from the INTRAGO I trial	Stefanie Brehmer, Germany
9:25 - 9:40 AM	INTRAGO II: An update	Kevin Petrecca, Canada
9:40 - 9:55 AM	5ALA+IORT: A sub-analysis of the INTRAGO II trial	Christopher Cifarelli, United States of America
9:55 - 10:10 AM	Recurrent Glioblastoma and IORT: A single-center experience	Chiara Negwer, Germany
10:10 - 10:25 AM	The Alcatraz-Strategy: a roadmap to break the connectivity barrier in malignant brain tumors	Matthias Schneider, Germany
10:25 - 10:55 PM	Break

	Session	Speaker
10:55 - 11:15 AM	Current Guidelines, clinical evidence and context for IORT	Ilinca Popp, Germany
11:15 - 11:30 AM	INTRAMET: Building the evidence for BM-IORT	Stefanie Brehmer, Germany
11:30 - 11:45 AM	Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes	Matthias Schneider, Germany
11:45 AM - 12:00 PM	Multicentric assessment of safety and efficacy of combinatorial adjuvant brain metastasis treatment by IORT and immunotherapy.	Gustavo Sarria, Germany
12:00 - 12:15 PM	Intraoperative radiotherapy after neurosurgical resection of brain metastases as institutional standard treatment	Henning Kahl, Germany
12:15 - 12:30 PM	LEXIMAT: Final nail in the coffin?	Stephanie Combs, Germany
12:30 - 12:45 PM	Coffee Break

	Session	Speaker
12:45 - 1:00 PM	Kypho-Intra Operative Radiation Therapy (IORT) for osteolytic metastatic spinal tumors (OMSTs)	Maged Ghaly, United States of America
1:00 - 1:15 PM	IORT combined with spinal stabilization surgery: a novel treatment strategy for spinal metastases based on a first single-center experience	Ehab Shiban, Germany

	Session	Speaker
1:15 - 1:30 PM	Closing remarks	Frank Giordano, Elena Sperk, Stephanie Combs, Germany

Chair Jens Gempt University Hospital Hamburg, Germany

Chair Christina Tsien McGill University Medical Center Montreal, Canada

Chair Chiara Negwer Technical University Munich, Germany

Venue

Conference Hotel

NH Collection München Bavaria Arnulfstraße 2 80335 Munich Germany

Accomodation

Within walking distance to the event venue in the heart of Munich there are several hotels.

We kindly ask you to make all travel arrangements, including the accommodation booking, yourself based on your individual preferences. Please note that the organizer does not cover any expenses for hotel, transfer, parking, or any additional expenses for you or your family members.

The event is officially hosted by ZEISS.

Navigate to location

Register for ILEXIUM 2024

Form is loading...

The personal data submitted via the registration form are being processed by ILEXIUM as well as its official sponsor Carl Zeiss Meditec AG and ZEISS subsidiaries for the execution of the ILEXIUM event.

In the light of compliance regulations² , we would like to inform you that, if necessary, you must obtain your employer’s permission and check local legislation regarding the content of the invitation.

If you want to have more information on data processing at ZEISS please refer to our data privacy notice.

¹
I hereby give Carl Zeiss Meditec AG, Göschwitzer Str. 51 52, 07745 Jena, Germany and related companies in accordance with Sections 15ff. German Stock Corporation Act (AktG), ("ZEISS") my permission to disseminate and publish the image(s)/films in which I appear (my "LIKENESS") in course of my participation of ILEXIUM which takes place on 27-28 June, 2024 in Munich, Germany, including for purposes of corporate advertising and the promotion of goods or services. My permission shall apply to all media (e.g., ZEISS homepage, Intranet and social media pages, printed materials such as product brochures etc.) with the exception of television and cinema. It shall also include digitization and editing (e.g., montage or retouching) of the LIKENESS, provided my legitimate interests are not violated. ZEISS shall be entitled to sub license the contractual rights of use pertaining to the LIKENESS to operators of internet platforms as social media platforms, to use the LIKENESS there as per the particular terms and conditions of the operators. This grant of rights is valid for 2 years from the date of the signing and expires thereafter. This consent is given free of charge.
²
To all participants for whom “Sunshine” applies: in accordance with the Open Payments (“Sunshine”) provision of the Patient Protection and Affordable Care Act (and similar state laws), the value of food and beverage is subject to public disclosure, and therefore will be reported in compliance with all applicable laws. State of Vermont HCPS: This event was sponsor ed by Carl Zeiss Meditec AG. Partaking of the food and beverages is prohibited under Vermont’s Gift Ban.